On 7 June 2013, orphan designation (EU/3/13/1133) was granted by the European Commission to ViroPharma SPRL, Belgium, for maribavir for the treatment of cytomegalovirus disease in patients with impaired cell-mediated immunity.
The sponsorship was transferred to ViroPharma SPRL, Belgium, in February 2009.
In February 2016, ViroPharma SPRL changed name to Shire Services BVBA.
The sponsorship was transferred to Shire Pharmaceuticals Ireland Limited, Ireland, in March 2016.
The sponsorship was transferred to Takeda Pharmaceuticals International AG Ireland Branch in September 2021.
Treatment of cytomegalovirus disease in patients with impaired cell-mediated immunity
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: